What Analysts Are Saying About Quest Diagnostics Stock
Portfolio Pulse from Benzinga Insights
Analysts have recently updated their ratings and price targets for Quest Diagnostics (NYSE:DGX), with a mix of 'Outperform', 'Hold', 'In-Line', 'Equal-Weight', and 'Neutral' ratings. The average 12-month price target has increased by 8.08% to $163.2. Quest Diagnostics shows strong financial performance with a notable net margin and ROE, despite facing challenges in revenue growth compared to peers.
October 23, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Quest Diagnostics has received updated analyst ratings, with a new average price target of $163.2, reflecting an 8.08% increase. Analysts have varied ratings from 'Outperform' to 'Neutral'. The company's financials are strong, with a high net margin and ROE, but it faces growth challenges compared to peers.
The increase in the average price target by 8.08% suggests positive sentiment among analysts, which could lead to a short-term price increase. The strong financial metrics like net margin and ROE further support a positive outlook. However, the company's revenue growth challenges compared to peers may temper expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100